Daily Briefing for October 29, 2026

Kennedy lets doctors compound six unapproved peptides, including BPC-157 The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source. Read the post and its sources Get the free email briefing Federal health officials will not take enforcement action against licensed physicians and state-licensed pharmacies that compound six unapproved peptides, including BPC-157 and TB-500, under a policy Health and Human Services posted Wednesday. The policy requires a patient-specific prescription, bulk ingredients from an FDA-registered manufacturer with a certificate of analysis, a single active ingredient and reporting of serious adverse events to MedWatch, according to the HHS policy document . The FDA had previously advised people not to use the peptides, The Independent reported . In other news, emergency physicians at 20 departments spent 2.4 fewer minutes on each note when they used an AI scribe, and Eli Lilly's investigational retatrutide produced more than twice the weight loss of Ozempic in a head-to-head type 2 diabetes trial. In this episode HHS will let physicians and pharmacies compound BPC-157, TB-500 and four other unapproved peptides without FDA enforcement AI scribes cut emergency physicians' active note time 2.4 minutes across 20 departments without raising 72-hour returns Lilly's retatrutide beats Ozempic head to head in type 2 diabetes, with about 21% weight loss vs. 9% at 80 weeks Zocdoc opens appointment booking to registered AI agents as agent traffic grows nearly 30-fold since July Voice-guided AI makes endoscopic ultrasound exams more complete in a randomized trial but adds about 2 minutes Caring text messages beat support calls for suicidal adolescents at 12 months, while adults did better with calls, trial finds